The Week

Hims & Hers Health (HIMS) fell 3.92% this week to close at $27.71, while the S&P 500 edged up 0.09%, leaving the stock about 4.01 percentage points behind. The week shaped up as a failed push higher: Monday opened near $28.67 and closed up at $29.58, Tuesday tagged the week’s high of $29.87 before fading, and the final three sessions drifted lower, with Thursday breaking below $28 on heavier volume and Friday hitting a low of $27.38 before settling at $27.71. The weekly range of 8.69% kept the stock inside the broad band between the July 30 low of $24.24 and the July 6 high of $39.05.

Key Events

The clearest company-specific line was international expansion: Hims & Hers announced on Monday its entry into Australia, marking its first move into Asia-Pacific, with GLP-1 weight-loss drugs and men’s health treatments offered there. On the regulatory and legal side, Friday brought reports that the FTC had sued over mislabelled GLP-1 medications, followed by several law firms seeking shareholders to lead securities class actions tied to the disclosure-driven share decline. Also on Friday, Chief Legal Officer Soleil Boughton disclosed the sale of 3,458 shares for roughly $98,000. These two threads sit close together in time and framed the week’s narrative, though the news and price action read as correlated rather than causal.

Analyst Ratings

As of the 3 September aggregate, 16 institutions cover Hims & Hers Health: 1 buy, 2 overweight, 11 hold, 1 underweight, and 1 with no opinion. The consensus rating is hold, with a consensus target of $31.23, about 12.71% above the $27.71 spot. Target prices range from $23 to $42, a wide spread that points to real disagreement on the outlook. Within the healthcare services industry, the stock ranks 8th out of 53 names on ratings, in the upper-middle tier.

The Week Ahead

The FTC case and the securities class-action efforts will extend into next week: whether more law firms solicit shareholders and whether management responds on labelling are the key company-level questions. On the macro calendar, Tuesday brings the NFIB Small Business Optimism Index, and Thursday is dense with initial jobless claims, final-demand PPI, existing home sales, and wholesale sales. PPI forecasts sit above the prior readings; a hotter print could feed a repricing of rate expectations and amplify swings in high-valuation growth names.

In Short

This week’s pullback coincided with a lawsuit disclosure and a lukewarm sell-side stance: the consensus rating is hold, 11 of 16 institutions are at hold, and only 3 are buy or overweight, yet the consensus target still sits about 12.71% above spot with a very wide target range. The stock is currently loss-making, at a negative 45.52x P/E and roughly 19.95x book, so growth expectations remain priced fairly high. Latest-session money flows show large-lot sellers against small- and mid-lot buyers, a mixed signal. What comes next hinges on whether the FTC action widens, how the Australia and GLP-1 rollout progresses, and how a richly valued stock absorbs macro data risk.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.